Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

Bristol-Myers Squibb (BMS)

Status

Treatments: Biological: Nivolumab plus Relatlimab FDC

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05170685

CA224-129

Details and patient eligibility

About

This is an expanded access designed to provide access to fixed-dose combination of nivolumab plus relatlimab for eligible participants.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria